- Home
- PHAT vs NXP Comparison
PHAT vs NXP Comparison
Compare PHAT & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NXP
- Stock Information
- Founded
- PHAT 2018
- NXP 1992
- Country
- PHAT United States
- NXP United States
- Employees
- PHAT N/A
- NXP N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- PHAT Health Care
- NXP Finance
- Exchange
- PHAT Nasdaq
- NXP Nasdaq
- Market Cap
- PHAT 769.0M
- NXP 741.7M
- IPO Year
- PHAT 2019
- NXP N/A
- Fundamental
- Price
- PHAT $13.55
- NXP $14.37
- Analyst Decision
- PHAT Strong Buy
- NXP
- Analyst Count
- PHAT 5
- NXP 0
- Target Price
- PHAT $17.60
- NXP N/A
- AVG Volume (30 Days)
- PHAT 1.3M
- NXP 70.0K
- Earning Date
- PHAT 10-30-2025
- NXP 01-01-0001
- Dividend Yield
- PHAT N/A
- NXP 4.04%
- EPS Growth
- PHAT N/A
- NXP N/A
- EPS
- PHAT N/A
- NXP 0.54
- Revenue
- PHAT $147,190,000.00
- NXP N/A
- Revenue This Year
- PHAT $213.65
- NXP N/A
- Revenue Next Year
- PHAT $91.41
- NXP N/A
- P/E Ratio
- PHAT N/A
- NXP $26.81
- Revenue Growth
- PHAT 460.30
- NXP N/A
- 52 Week Low
- PHAT $2.21
- NXP $12.91
- 52 Week High
- PHAT $19.50
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- PHAT 58.66
- NXP 46.84
- Support Level
- PHAT $13.02
- NXP $14.26
- Resistance Level
- PHAT $16.08
- NXP $14.55
- Average True Range (ATR)
- PHAT 1.05
- NXP 0.12
- MACD
- PHAT -0.02
- NXP -0.03
- Stochastic Oscillator
- PHAT 44.88
- NXP 28.21
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.